Sinovac Biotech (SVA) Receives Daily News Sentiment Score of 0.09
Press coverage about Sinovac Biotech (NASDAQ:SVA) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sinovac Biotech earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.1988612620084 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Sinovac Biotech, Ltd. (SVA) Lifted to Buy at BidaskClub (americanbankingnews.com)
- Sinovac Biotech Announces Receipt of Delisting Determination Letter from Nasdaq (finance.yahoo.com)
- Sinovac Biotech (SVA) & Its Rivals Critical Analysis (americanbankingnews.com)
- Comparing Sinovac Biotech (SVA) and Its Competitors (americanbankingnews.com)
- Contrasting Sinovac Biotech (SVA) & Its Peers (americanbankingnews.com)
Shares of Sinovac Biotech (SVA) traded up $0.07 on Friday, reaching $7.25. The company had a trading volume of 200,828 shares, compared to its average volume of 100,147. Sinovac Biotech has a 1 year low of $4.60 and a 1 year high of $7.32.
Separately, BidaskClub upgraded Sinovac Biotech from a “hold” rating to a “buy” rating in a research note on Friday.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/sinovac-biotech-sva-receives-daily-news-sentiment-score-of-0-09/1681470.html.
About Sinovac Biotech
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.